Patents by Inventor Oistein Ihle

Oistein Ihle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11725063
    Abstract: Provided is an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: August 15, 2023
    Assignee: Rallybio IPA, LLC
    Inventors: Terje Michaelsen, Oistein Ihle, Tor Brynjar Stuge, Anne Husebekk, Heidi Tiller, Mariana Eksteen, Bjorn Ragnar Skogen
  • Publication number: 20210189005
    Abstract: Provided is an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
    Type: Application
    Filed: December 9, 2020
    Publication date: June 24, 2021
    Inventors: Terje Michaelsen, Oistein Ihle, Tor Brynjar Stuge, Anne Husebekk, Heidi Tiller, Mariana Eksteen, Bjorn Ragnar Skogen
  • Patent number: 10882919
    Abstract: The present invention provides an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: January 5, 2021
    Assignee: Rallybio IPA, LLC
    Inventors: Terje Michaelsen, Oistein Ihle, Tor Brynjar Stuge, Anne Husebekk, Heidi Tiller, Mariana Eksteen, Bjorn Ragnar Skogen
  • Publication number: 20170121422
    Abstract: The present invention provides an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
    Type: Application
    Filed: March 31, 2015
    Publication date: May 4, 2017
    Applicants: UNIVERSITETET I TROMSO - NORGES ARKTISKE UNIVERSIT ET, UNIVERSITY HOSPITAL OF NORTH NORWAY, NORINNOVA TECHNOLOGY TRANSFER AS
    Inventors: Terje MICHAELSEN, Oistein IHLE, Tor Brynjar STUGE, Anne HUSEBEKK, Heidi TILLER, Mariana EKSTEEN, Bjorn Ragnar SKOGEN
  • Publication number: 20140370533
    Abstract: A method of detecting active TB in a patient comprising providing at least one peptide comprising an amino acid sequence with at least 80% sequence identity to a sequence selected from SEQ. ID NOS. 1 to 8, or an antigenic fragment thereof and contacting the peptide with a biological sample obtained from the patient. The presence of an antibody in the sample binding to the peptide is indicative of active TB in the patient.
    Type: Application
    Filed: September 19, 2012
    Publication date: December 18, 2014
    Applicant: Norwegian Institute of Public Health
    Inventors: Oistein Ihle, Terje Einar Michaelsen, Carol Joanne Church Holm-Hansen